502697-62-3

Basic information

• Product Name: Carbamic acid, [(3R)-3-hydroxy-3-phenylpropyl]-, ethyl ester
• CAS NO: 502697-62-3
• Molecular Formula: C12H17NO3
• Molecular Weight: 223.272
• Mol File: 502697-62-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(3R)-3-hydroxy-3-phenylpropyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3R)-3-hydroxy-3-phenylpropyl]-, ethyl ester(502697-62-3)
• EPA Substance Registry System: Carbamic acid, [(3R)-3-hydroxy-3-phenylpropyl]-, ethyl ester(502697-62-3)

Safety Data

• Hazardous Substances Data: 502697-62-3(Hazardous Substances Data)

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 138750-31-9 (1R)-3-amino-1-phenyl-1-propanol 
• 614-16-4 Benzoylacetonitrile 
• 96-09-3 styrene oxide 
• 73627-97-1 3-hydroxy-3-phenylpropanenitrile 
• 198561-42-1 (R)-3-acetyloxy-3-phenylpropanenitrile 

Downstream Products

• 112066-66-7 (S)-N-methyl-3-(2-methoxyphenoxy)-3-phenyl-1-propanamine 
• 105314-53-2 (S)-N-methyl-3-(2-methylphenoxy)-3-phenyl-1-propanamine 
• 100568-02-3 (S)-fluoxetine 
• 54910-89-3 (R)-fluoxetine 
• 115290-81-8 (R)-N-methyl-3-phenyl-3-hydroxypropylamine 
• 191733-29-6 (S)-N-(ethoxycarbonyl)-3-(2-methoxyphenoxy)-3-phenyl-1-propanamine 
• 191733-28-5 (S)-N-(ethoxycarbonyl)-3-(2-methylphenoxy)-3-phenyl-1-propanamine 
• 191733-30-9 (S)-N-(ethoxycarbonyl)-3-(4-(trifluoromethyl)phenoxy)-3-phenyl-1-propanamine 

Relevant articles and documents

Polymer-supported chiral sulfonamide catalyzed one-pot reduction of β-keto nitriles: A practical synthesis of (R)-fluoxetine and (R)-duloxetine

Enantioselective reduction of β-keto nitriles to optically active 1,3-amino alcohols has been carried out in one step using an excess of borane-dimethyl sulfide complex as a reductant and a polymer-supported chiral sulfonamide as a catalyst with moderate to high enantioselectivity. The facile and enantioselective method to prepare optically active 1,3-amino alcohols to be converted into 3-aryloxy-3-arylpropylamine-type antidepressant drugs (R)-fluoxetine, and (R)-duloxetine is also reported.